Andreas Becker

A Phase 1 Study of the DNA-PK Inhibitor Peposertib in Combination With Radiation Therapy With or Without Cisplatin in Patients With Advanced Head and Neck Tumors

Michael A. Samuels, Johan Falkenius, Voichita Bar‐Ad et al. · International Journal of Radiation Oncology*Biology*Physics · 2023 · 66 citations · Full text

Medicine, Oncology, Pharmacology +15

Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration‐QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers

Andreas Becker, Emily C. Martin, David Mitchell et al. · Clinical and Translational Science · 2019 · 35 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer

Paul B. Romesser, Jaume Capdevila, Rocio García‐Carbonero et al. · Clinical Cancer Research · 2023 · 35 citations · Full text

Medicine, Oncology, Pharmacology +17

Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers

Andreas Johne, Holger Scheible, Andreas Becker et al. · Investigational New Drugs · 2020 · 24 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

A first-in-human phase I study of ATR inhibitor M1774 in patients with solid tumors.

Timothy A. Yap, Anthony W. Tolcher, Elizabeth Ruth Plummer et al. · Journal of Clinical Oncology · 2021 · 21 citations

Medicine, Oncology, Pharmacology +16